What is the current share price of SK Finance?
SK Finance operates primarily as a non-banking financial company focusing on vehicle financing and micro, small, and medium enterprise loans. Evaluating its exact equity valuation requires referencing official private equity updates or primary market filings, as specific secondary share pricing depends on pre-IPO rounds or periodic corporate valuation assessments before full public stock exchange listings.
Related FAQs
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) trades at a market price of approximately $21.53 per share.
SK Group is one of the largest multinational conglomerates, operating diverse business subsidiaries across energy, chemicals, telecommunications, and advanced technology sectors.
SK Life Sciences, operating as the United States subsidiary of SK Biopharmaceuticals, generates multi-million-dollar annual revenues driven primarily by the commercialization and prescription sales of its flagship central nervous system medications a...
SK Finance Limited is widely regarded as a well-established and reputable non-banking financial company in India, specializing in vehicle financing and micro, small, and medium enterprise lending.
SK Biopharmaceuticals, a prominent South Korean innovative healthcare and pharmaceutical enterprise listed on the Korea Exchange, maintains a market capitalization fluctuating around 4.2 billion to 4.5 billion US dollars.
SK Bioscience played a direct and notable role in the global response to the pandemic by developing Skycovione, which marked South Korea's first domestically produced COVID-19 vaccine utilizing advanced protein subunit technology.
SK bioscience Co., Ltd. is publicly traded on the Korea Exchange under the official stock ticker symbol 302440.
SK Pharma generally refers to the pharmaceutical and life sciences business sectors managed under the broader umbrella of South Korea's SK Group, encompassing specialized corporate entities like SK Biopharmaceuticals and SK bioscience.
SK Bioscience Co., Ltd. operates as a key biotechnology and vaccine-manufacturing subsidiary of SK discovery, which functions as the intermediate holding company under South Korea's massive SK Group conglomerate.
Day One Biopharmaceuticals achieved significant clinical and corporate milestones with the advancement of its lead targeted oncology therapies, highlighted by regulatory submissions and commercialization efforts for pediatric brain cancer treatments.
SK Group is the second-largest chaebol (conglomerate) in South Korea, comprising over a hundred subsidiary and affiliate companies operating across advanced technology, energy, telecommunications, and biotechnology.